1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Lung Cancer Diagnostics Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis

Lung Cancer Diagnostics Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis

  • November 2021
  • 135 pages
  • ID: 6187085
  • Format: PDF
  • Renub Research

Summary

Table of Contents

Lung Cancer Diagnostics Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis

Globally, lung cancer occurs when cells divide in the lungs uncontrollably—further causing tumours to grow, which reduces a person’s ability to breathe and spread to other parts of the body.
Moreover, lung cancer is amongst the most common cancer and the leading cause of cancer-related death worldwide. Smoking is a significant risk factor, though everyone who develops lung cancer does not have a smoking history. Lung cancer can be fatal. Nevertheless, effective diagnoses and treatments are improving the outlook. According to the Renub Research, Lung Cancer Diagnostics Market is projected to reach US$ 3.6 Billion by 2027.

Types of Lung Cancer Prevailing in the Global Market
The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope. Small cell lung cancer (SCLC) spreads promptly in the body, making detecting this cancer at an early stage. However, only about 10% of the fatalities are small cell lung cancers. There are two dominant subtypes of SCLC, combined small-cell lung carcinoma and small-cell lung carcinoma.

Non-small cell lung cancer (NSCLC) is the unique form of cancer and accounts for 85% of lung cancer cases. Moreover, multiple subtypes of NSCLC include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less frequent types of NSCLCs. As per our analysis, non-small cell lung cancer dominates small cell lung cancer around the world.

Worldwide Lung Cancer Diagnosis Industry will grow with a CAGR of 7.75% during 2021 to 2027

Imaging tests activity is the primary screening technique used for lung cancer diagnosis. Imaging tests assist as the initial screening mechanism for lung cancer diagnostics and are helpful throughout the treatment period. Wherein the high usage rates of various imaging techniques, including X-rays, Magnetic resonance imaging (MRI) scans (which use magnetic fields), Ultrasound (which uses sound waves) and Nuclear tests (which use radioactive substances to trace) are involved. Moreover, if cancer has spread, imaging tests can also reveal changes to bones and other organs. Consequently, helping to track treatment progress and capture the highest market share in the Lung Cancer Diagnostics Market.

Global Lung Cancer Diagnostics Market Size was US$ 2.3 Billion in 2021

Globally, lung cancer patients visit the hospitals & clinics for cancer-related and unrelated reasons more often than patients visiting diagnostics centres and research institutes with their lung cancer-related issues. Further, this results in the dominance of the hospitals & clinics dealing in admissions and lung cancer diagnosis. Moreover, as the patients frequently require emergency medical care due to acute unbearable symptoms and life-threatening conditions, hospitals & clinics serve as immediate help. As per our analysis, hospitals dominate the end-user segment in the Lung Cancer Diagnostics Market.

North America is the largest Lung Cancer Diagnosis Market and expected to remain its dominance in forecast period

North America, Europe and the Asia Pacific are analyzed at the regional forefront in our report. As per our analysis, North America is identified as the largest regional market with the highest market share throughout the forecasted period. The largest market share is attributed to the increased market invasion rates of technologically advanced products, the increasing patient awareness, and the growing smoking prevalence level in the region.

In addition, the presence of a favourable reimbursement framework (wildly succeeding the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure is expected to promote the usage rates of diagnostics devices in North America. Initiatives, such as smoking suspension programs administered by the American Lung Association (ALA) and campaigns to enhance knowledge of the symptoms of lung cancer, are anticipated to boost the regional market growth further.

Besides, Asia Pacific is projected to capture a lucrative growth in market share during the projection period. Major factors accountable for the fastest growth exhibited in the Asia Pacific include the rising penetration of advanced lung cancer diagnostic tools in the region and the increasing awareness about the disease symptoms.

Competitive Landscape Existing in the Market
The lung cancer diagnostics market is highly fragmented, with a large number of local and international players. Key players adopt different growth policies to magnify their market presence, including partnerships, agreements, collaborations, new product launches, geographical augmentations, mergers and acquisitions. Some of the chief players in the industry are Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG.

Recent Launches in Lung Cancer Diagnosis Field
In September 2020, Illumina acquired GRAIL, a healthcare company concentrated in multi-cancer early apprehension, for about USD 8 billion. The acquisition will also combine the company’s latest product, Galleri multi-cancer screening test.

In June 2020, Roche announced to launch ’uPath PD-L1 (SP263), a CE-IVD marked automated digital pathology algorithm for detecting non-small cell lung cancer. It is an image analyzer that supports diagnosing non-small cell lung cancer.

COVID-19 Pandemic affect on the Lung Cancer Diagnostics

At the origin of the COVID-19 pandemic, elective medical procedures, including lung cancer screening, were principally put on hold to prioritize urgent necessities and reduce the risk of the spread of COVID-19 in healthcare settings at the beginning of 2021. One effect of this has been a significant drop in the lung cancer diagnostics industry compared to 2020 as the pandemic started spreading at a rapid pace in H1 of 2021. Most healthcare facilities were offering elective procedures again, including lung cancer diagnostic declining the all over market in 2021.

This latest report “Lung Cancer Diagnostic Market, Global Forecast By Diagnosis Test Type (Imaging Test, Biopsy, Sputum Cytology, Molecular Test and Others), Lung Cancer Type (Small-cell Lung Cancer Diagnostics and Non-Small-cell Lung Cancer Diagnostics), End-User (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others), Region (North America, Europe, Asia Pacific and Rest of World), Companies (Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG)” provides a detailed analysis of Lung Cancer Diagnostic Industry.

Diagnosis Test Type – Global Lung Cancer Diagnostics Market has been covered from 5 viewpoints:
1. Imaging Test
2. Biopsy
3. Sputum Cytology
4. Molecular Test
5. Others

Lung Cancer Type – Global Lung Cancer Diagnostics Market has been covered from 2 viewpoints:
1. Small-cell Lung Cancer Diagnostics
2. Non-Small-cell Lung Cancer Diagnostics

Non-Small-cell Lung Cancer Diagnostics has been segmented into 4 viewpoints:
1. Adenocarcinoma
2. Squamous Cell Carcinoma
3. Large cell carcinoma
4. Others and not otherwise specified

End-User – Global Lung Cancer Diagnostics Market has been covered from 4 viewpoints:
1. Hospitals & Clinics
2. Diagnostic Centers
3. Research Institute
4. Others

Regions – Global Lung Cancer Diagnostics Market has been covered from 4 viewpoints:
1. North America
2. Europe
3. Asia Pacific
4. ROW

Company Insights:
• Overviews
• Recent Developments
• Revenues

Company Analysis:
1. llumina, Inc.
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc
4. QIAGEN N.V.
5. Roche Holding AG.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Interventional Oncology Market Research Report by Procedure, by Cancer Type, by End Users, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 3949
  • January 2022
  • 188 pages

Interventional Oncology Market Research Report by Procedure (Ablation, Particle Embolization, and Radiation Therapy), by Cancer Type (Bone Metastasis, Breast Cancer, and Kidney Cancer), by End Users, by ...

  • World
  • Cancer
  • Breast Cancer
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on